Physician profile
Craig A Smith
NPI 1225098031
$15,473.47
in general payments reported to CMS, 2019-2025
31 companies · $3,633 in 2025
The $3,633 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,784 · 2020: $736 · 2021: $268 · 2022: $1,798 · 2023: $992 · 2024: $5,263 · 2025: $3,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,117 · Travel and Lodging: $4,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,116.69 |
| Travel and Lodging | $4,771.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $4,057.18 | 2021-2025 | Urolift, Barrigel |
| Axonics, INC. | $2,733.86 | 2021-2024 | Axonics, Bulkamid |
| Procept Biorobotics Corporation | $1,515.65 | 2019-2025 | Aquabeam System, Aquabeam Robotic System |
| Neotract INC. | $1,361.35 | 2019-2020 | |
| Medtronic, INC. | $1,350.08 | 2023-2025 | Altaviva, Interstim |
| Bluewind Medical | $1,106.74 | 2024-2025 | Revi |
| Olympus America INC. | $594.41 | 2022-2025 | Itind System, Soltive |
| Sumitomo Pharma America, INC. | $330.53 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $316.80 | 2019-2023 | |
| Boston Scientific Corporation | $314.24 | 2019-2025 | Rezum Generator, Axonics |
| Medtronic USA, INC. | $274.11 | 2020 | |
| Astellas Pharma US INC | $178.90 | 2022-2024 | Xtandi |
| Endo USA, INC. | $162.46 | 2024-2025 | Xiaflex |
| Urogen Pharma, INC. | $157.91 | 2024 | |
| 180 Medical, INC. | $124.92 | 2024-2025 | Gentlecath, Wellspect, Gentlecath Glide |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $110.44 | 2024 | Lynparza |
| Genzyme Corporation | $99.79 | 2019 | |
| Myovant Sciences INC. | $99.68 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $81.86 | 2019 | |
| Halozyme INC | $75.23 | 2023 | |
| Endo Pharmaceuticals INC. | $71.50 | 2019-2023 | Xiaflex, Aveed, Edex |
| Tolmar, INC. | $56.22 | 2025 | Eligard, Jatenzo |
| Urovant Sciences INC | $54.43 | 2022 | |
| Antares Pharma, INC. | $47.33 | 2024-2025 | Xyosted, Tlando |
| Coloplast Corp | $43.17 | 2022-2024 | |
| Becton, Dickinson and Company | $41.52 | 2023 | Bard Urinary Drainage Bag |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.63 | 2025 | Azmiro |
| Ferring Pharmaceuticals INC. | $21.41 | 2024 | Adstiladrin |
| Laborie Medical Technologies Corp. | $21.20 | 2023 | |
| Allergan, INC. | $16.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.